Antiretroviral drug targeting human endogenous retrovirus
US10894820B2 · kind B2 · utility
0Cited by
3References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2019 |
| Grant date | Jan 19, 2021 |
| Priority date | — |
| Expiry date | Mar 22, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/10011
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.